Cooley advised Si-Bone on its $124.2 million initial public offering of 8,280,000 shares of common stock. Matthew Hemington and John McKenna led the Cooley team advising Si-Bone.
Morgan Stanley and Merrill Lynch acted as the lead book-running managers for the offering. Canaccord Genuity and JMP Securities acted as co-managers for the offering.
Si-Bone is a medical device company that has pioneered a treatment for sacroiliac joint dysfunction that often causes severe lower back pain. The company’s shares now trade on the Nasdaq Global Market under the symbol “SIBN.”